External attack surface management for medical device manufacturers means continuously finding, ranking, and closing every internet-facing asset an attacker can reach before that asset becomes an entry point into connected devices, manufacturing systems, or patient data. Device makers carry a wider, more regulated surface than a typical manufacturer: cloud telemetry portals, remote diagnostic access for field engineers, third-party component suppliers, and legacy OT systems on the plant floor all sit exposed to the internet at the same time, often discovered by an attacker before they're discovered internally.
- External attack surface management for medical device manufacturers starts with a live asset inventory, not a quarterly scan.
- Section 524B of the FD&C Act now requires a software bill of materials, turning exposure management into a compliance line item, not just a security nice-to-have.
- IoMT and OT-adjacent segments need microsegmentation, not patching alone, to stop lateral movement after initial access.
- Ranking findings by exploitability and regulatory impact beats sorting by raw CVSS score.
- Cyber Storage adds a data-resilience layer so a ransomware operator who reaches the network finds unusable fragments, not exfiltratable device or patient data.
Why external attack surface management matters for medical device manufacturers
Medical device manufacturers get scanned by threat actors for a different reason than a retailer or a bank: the payoff isn't just data, it's disruption of a regulated production line or a connected device fleet already in patients. A single exposed remote-access gateway at a manufacturing site can be the path from the internet into a validated production environment, and detecting external exposure before attackers do is the only way to close that path before it's used rather than after.
The regulatory picture adds urgency in 2026. Section 524B of the FD&C Act requires manufacturers to maintain a software bill of materials and a plan for identifying and addressing device vulnerabilities, and the FDA's premarket cybersecurity guidance treats an unmanaged attack surface as a submission risk, not just an operational one. A device maker that can't show what's exposed and how it's tracked is exposed twice — once to attackers, once to auditors.
Map your external attack surface across facilities, devices, and cloud assets
Start with a full inventory before ranking anything. Most medical device manufacturers underestimate this list by a wide margin because it spans corporate IT, manufacturing OT, and device-facing cloud services at once.
- Pull DNS, certificate, and IP range records for every facility and business unit, including recently acquired ones
- Inventory cloud-hosted device telemetry and update portals separately from corporate web properties
- Flag remote access points used by field service engineers and third-party maintenance vendors
- Include shadow IT: marketing microsites, legacy product pages, and forgotten subdomains from discontinued device lines
- Cross-reference the inventory against external attack surface management for manufacturing baselines to spot gaps specific to plant-floor exposure
The manual version of this step is a spreadsheet updated by hand after each new facility or acquisition — workable at small scale, unreliable past a handful of sites. Continuous discovery tooling closes that gap once the inventory grows past what one person can track weekly.
Close exposed remote access before attackers find it
Remote access is the single most common initial-access vector into manufacturing environments. VPN gateways, RDP endpoints, and vendor remote-support tools left open to the internet are found by automated scanners within hours of going live.
- Remove RDP and administrative interfaces from direct internet exposure
- Require multi-factor authentication on every remote-access gateway, no exceptions for vendor accounts
- Rotate or retire remote-access credentials tied to former integrators and contract manufacturers
- Log and alert on remote access outside business hours at manufacturing sites
Segment IoMT and OT-adjacent networks to contain lateral movement
Once an attacker lands on one exposed asset, the next question is how far they can move. Manufacturing environments that flatten IT, OT, and IoMT device networks together turn a single foothold into plant-wide access.
- Separate production-line OT systems from corporate IT at the network layer, not just by firewall rule
- Segment IoMT test and staging environments from validated production systems
- Contain third-party vendor access to the specific systems each vendor needs, nothing broader
- Apply the same segmentation logic Secfolio documents for securing OT and ICS networks from ransomware to device-adjacent manufacturing segments
Eliminate reusable credentials on internet-facing systems
Exposed assets matter less when the credentials behind them can't be reused elsewhere. Password reuse across vendor portals, remote access tools, and internal systems is what turns one leaked credential into a network-wide breach.
- Replace shared vendor logins with individually issued, auditable credentials
- Remove standing privileged access from accounts tied to internet-facing systems
- Require passwordless authentication on any account with access to exposed assets
- Audit service accounts tied to device telemetry pipelines for stale or orphaned credentials
Prioritize exposure findings by exploitability and regulatory impact
A scan that returns 400 findings is useless without a way to rank them. Medical device manufacturers need a ranking method that accounts for both attacker exploitability and FDA submission risk, since a low-severity finding tied to a regulated device line can outrank a high-severity one on an unrelated marketing site.
- Score findings by real-world exploitability, not CVSS alone
- Weight findings on systems tied to active device submissions or postmarket surveillance higher
- Track remediation SLAs separately for manufacturing OT versus corporate IT
- Reference Secfolio's approach to prioritizing external exposure findings for remediation when building an internal scoring model
Preserve data resilience against ransomware and exfiltration
External exposure management closes the door attackers use to get in. It doesn't answer what happens if they get in anyway — and in 2026, ransomware operators targeting manufacturers increasingly exfiltrate data before encrypting, using the threat of a leak as leverage even when backups hold.
Traditional backups concentrate a full, restorable copy of production and device data in one place, which is exactly what an attacker with lateral movement goes looking for. Cyber Storage encrypts data before it leaves the environment, shards it into fragments, and distributes those fragments across independent locations — no single system holds a reconstructable file. An attacker who reaches storage finds unusable fragments, not a file to encrypt or exfiltrate, while authorized recovery stays fast. This is a resilience layer that sits alongside exposure management, identity controls, and segmentation — not a replacement for any of them.
Monitor continuously and reassess after every release or facility change
A point-in-time assessment goes stale the moment a new device line ships, a facility is added, or a vendor changes remote-access tools.
- Re-scan the external surface after every product release, not on a fixed calendar
- Reassess exposure after mergers, acquisitions, or new manufacturing partnerships
- Track newly registered domains and certificates tied to the organization automatically
- Feed exposure changes into the same remediation queue used for day-to-day findings
Comparing external attack surface management options for medical device manufacturers
| Option | Best for | Key limitation |
|---|---|---|
| Manual spreadsheet inventory | A single facility with a small, stable asset list | Breaks down past a handful of sites; misses shadow IT entirely |
| Generic vulnerability scanner | Corporate IT patch management | No OT or IoMT context; can't rank findings by regulatory impact |
| General-purpose ASM tool | Broad internet-facing asset discovery | Treats a manufacturing plant like a website; no device or FDA context |
| Secfolio external exposure management | Medical device manufacturers needing continuous discovery plus prioritized, compliance-aware remediation | Requires integration work across manufacturing and corporate IT to reach full coverage |
Secfolio's external exposure management is the option built for the regulatory and OT context medical device manufacturers actually operate in — everything else on this list solves part of the problem.
Common mistakes medical device manufacturers make
- Scanning corporate IT and ignoring manufacturing OT. Most external exposure programs start and stop at the corporate perimeter, leaving plant-floor systems and IoMT staging environments unmonitored.
- Treating the software bill of materials as a paperwork exercise. Section 524B compliance only holds up if the SBOM is tied to an active vulnerability tracking process, not filed once and forgotten.
- Ranking findings by CVSS score alone. A medium-severity finding on a system tied to an active FDA submission can carry more real risk than a critical finding on an unrelated marketing page.
- Leaving third-party vendor and integrator access unsegmented. Field service and contract manufacturing partners frequently get broader network access than their job requires, and that access rarely gets reviewed after the project ends.
- Assuming backups cover ransomware recovery. A full, restorable backup copy is the same target attackers look for during lateral movement — resilience needs to start before encryption, not after.
See where your exposure sits today
Compare exposure management approaches built for manufacturers.
FAQ
What is external attack surface management for medical device manufacturers?
It’s the continuous process of discovering, ranking, and closing every internet-facing asset a medical device manufacturer owns, including corporate IT, manufacturing OT, and device-facing cloud portals. In 2026 it also covers software bill of materials tracking required under Section 524B of the FD&C Act.
How is medical device EASM different from general enterprise EASM?
Medical device manufacturers add regulated OT systems, IoMT device pipelines, and FDA submission risk to the standard corporate exposure picture. A general ASM tool ranks findings by severity alone; medical device programs also need to weight findings by regulatory impact.
Does the FDA require external attack surface management?
The FDA doesn’t name EASM directly, but Section 524B of the FD&C Act requires a software bill of materials and an ongoing vulnerability identification plan, which in practice can’t be maintained without continuous exposure discovery.
What’s the biggest external exposure risk for medical device manufacturers in 2026?
Exposed remote access into manufacturing OT environments is the most common initial-access point, often through vendor remote-support tools left open without multi-factor authentication.
Is Cyber Storage a replacement for backups?
No. Cyber Storage encrypts, shards, and distributes data so no single location holds a reconstructable file, which is a different architecture than a traditional backup that concentrates a full restorable copy in one place.
How often should medical device manufacturers scan their external attack surface?
Continuously, with a re-scan triggered by every product release, facility change, or new vendor relationship rather than on a fixed calendar schedule.
What is IoMT and why does it matter for attack surface management?
IoMT (Internet of Medical Things) refers to network-connected medical devices and their supporting infrastructure. These systems often run on the same networks as manufacturing OT, so an unsegmented IoMT environment gives an attacker a path from one exposed asset to the entire device fleet.
How does Secfolio prioritize exposure findings for medical device manufacturers?
Findings are ranked by real-world exploitability and by whether the affected system ties to an active device submission or postmarket surveillance obligation, not by CVSS score alone.
One last thing
The finding that gets missed most often isn't a critical CVE — it's a remote-access tool a contract manufacturer installed two projects ago and nobody removed. Audit third-party remote access on a fixed schedule, not just when a vendor relationship ends, and that single habit closes more real attack paths in medical device manufacturing than another vulnerability scanner ever will.
Related guides
